Cargando…
High-throughput approaches to discover novel immunomodulatory agents for cancer
The clinical success of immunomodulatory thalidomide derivatives has renewed the general interest in immunomodulatory anticancer compounds and prompted us to develop a high-throughput system to quantify immune effector-cell activity. We documented that the interaction between cancer cells, their str...
Autores principales: | McMillin, Douglas W., Mitsiades, Constantine S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518518/ https://www.ncbi.nlm.nih.gov/pubmed/23243609 http://dx.doi.org/10.4161/onci.21058 |
Ejemplares similares
-
Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014) -
Ethanolamine: A novel anti-aging agent
por: Rockenfeller, Patrick, et al.
Publicado: (2015) -
ImmTACs: Novel bi-specific agents for targeted cancer therapy
por: Oates, Joanne, et al.
Publicado: (2013) -
LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
por: Camilio, Ketil André, et al.
Publicado: (2014) -
Cellular immunotherapy directed against human cytomegalovirus as a novel approach for glioblastoma treatment
por: Schuessler, Andrea, et al.
Publicado: (2014)